Bisphosphonate drug holiday: who, when and how long

The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid

(2014) John T. Grbic et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Bisphosphonates in the Treatment of Osteoporosis

(2012) Dima L. Diab et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Bisphosphonate therapy for osteoporosis: The long and short of it

(2012) Juliet E Compston et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Does osteoporosis therapy invalidate FRAX for fracture prediction?

(2012) William D Leslie et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonates for Osteoporosis — Where Do We Go from Here?

(2012) Marcea Whitaker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

(2012) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonates for postmenopausal osteoporosis

(2011) Richard Eastell et al.   BONE

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial

(2010) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur

(2010) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL